SCHEMBL3754460

SCHEMBL3754460

CSc1ccc(CC(=O)Nc2sc3c(c2-c2nc4ccccc4s2)CCN(C)C3)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.72
TP53 P04637 2/20 0.72
RXFP1 Q9HBX9 1/20 0.70
APEX1 P27695 8/20 0.70
UHRF1 Q96T88 1/20 0.63
MAPT P10636 3/20 0.58
KDM4E B2RXH2 3/20 0.57
NPC1 O15118 2/20 0.57
ALDH1A1 P00352 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
MYC P01106 1/20 0.56
MEN1 O00255 2/20 0.55
HTT P42858 2/20 0.55
KMT2A Q03164 2/20 0.55
USP2 O75604 1/20 0.55
POLB P06746 1/20 0.55
RECQL P46063 1/20 0.55
RAB9A P51151 1/20 0.55
BLM P54132 1/20 0.55
HPGD P15428 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1495006 0.86 APEX1 (0.80) LMNATP53RXFP1APEX1UHRF1
SCHEMBL13058126 0.83 LMNA (0.89) LMNATP53RXFP1APEX1UHRF1
SCHEMBL13735042 0.83 APEX1 (1.00) LMNATP53RXFP1APEX1UHRF1
SCHEMBL1495080 0.82 MAPT (0.77) LMNATP53RXFP1APEX1UHRF1
SCHEMBL3754468 0.82 APEX1 (0.68) LMNATP53RXFP1APEX1UHRF1
SCHEMBL13832447 0.81 APEX1 (0.77) LMNATP53APEX1UHRF1MAPT
SCHEMBL3754448 0.81 APEX1 (0.67) LMNATP53RXFP1APEX1UHRF1
SCHEMBL3753732 0.81 LMNA (0.85) LMNATP53RXFP1APEX1UHRF1
SCHEMBL3749177 0.81 APEX1 (0.71) LMNATP53RXFP1APEX1UHRF1
SCHEMBL13833618 0.81 APEX1 (0.80) LMNATP53RXFP1APEX1UHRF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2010-11-25 US claimed
WO-2008020438-A2 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD (IL) 2008-02-21 WO claimed
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2010-11-25 US disclosed
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2010-11-25 US disclosed
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2010-11-25 US disclosed
WO-2008020438-A2 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD (IL) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF HPSE, HDGF, HPGDS LMNA 4715/4885TP53 847/4885RXFP1 3491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.